Outlook

Outlook 2011 adjusted

27 October 2011

Total revenue 2011 is expected to exceed € 3.1 billion due to slower generic competition to Keppra® and supported by the performance of core medicines.
In 2011, UCB’s recurring EBITDA is expected to reach approximately € 680 million. Core EPS 2011 are expected to exceed € 1.80, based on a 178.5 million weighted average number of outstanding shares.